NCT00592579View on ClinicalTrials.gov

A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 31, 2001

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
Relapsed Multiple MyelomaPlateau Phase Multiple Myeloma
Interventions
DRUG

2-methoxyestradiol

800 mg of 2ME2 (capsules) administered orally every 12 hours for a total daily dose of 1600 mg.

Trial Locations (2)

55905

Mayo Clinic, Rochester

02115

Dana Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

CASI Pharmaceuticals, Inc.

INDUSTRY